319 related articles for article (PubMed ID: 36263054)
1. Impact of natural killer cells on outcomes after allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis.
Mushtaq MU; Shahzad M; Shah AY; Chaudhary SG; Zafar MU; Anwar I; Neupane K; Khalid A; Ahmed N; Bansal R; Balusu R; Singh AK; Abhyankar SH; Callander NS; Hematti P; McGuirk JP
Front Immunol; 2022; 13():1005031. PubMed ID: 36263054
[TBL] [Abstract][Full Text] [Related]
2. Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.
Theurich S; Fischmann H; Shimabukuro-Vornhagen A; Chemnitz JM; Holtick U; Scheid C; Skoetz N; von Bergwelt-Baildon M
Cochrane Database Syst Rev; 2012 Sep; (9):CD009159. PubMed ID: 22972135
[TBL] [Abstract][Full Text] [Related]
3. Outcomes with CD34-Selected Stem Cell Boost for Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
Shahzad M; Siddiqui RS; Anwar I; Chaudhary SG; Ali T; Naseem M; Ahmed TF; Ahmed Z; Khurana S; Ahmed N; Balusu R; Singh AK; Hematti P; Callander NS; Abhyankar SH; McGuirk JP; Mushtaq MU
Transplant Cell Ther; 2021 Oct; 27(10):877.e1-877.e8. PubMed ID: 34284148
[TBL] [Abstract][Full Text] [Related]
4. Outcomes with mismatched unrelated donor allogeneic hematopoietic stem cell transplantation in adults: A systematic review and meta-analysis.
Mushtaq MU; Shahzad M; Tariq E; Iqbal Q; Chaudhary SG; Zafar MU; Anwar I; Ahmed N; Bansal R; Singh AK; Abhyankar SH; Callander NS; Hematti P; McGuirk JP
Front Oncol; 2022; 12():1005042. PubMed ID: 36276084
[TBL] [Abstract][Full Text] [Related]
5. Improved NK Cell Recovery Following Use of PTCy or Treg Expanded Donors in Experimental MHC-Matched Allogeneic HSCT.
Wolf D; Barreras H; Copsel SN; Komanduri KV; Levy RB
Transplant Cell Ther; 2022 Jun; 28(6):303.e1-303.e7. PubMed ID: 35302008
[TBL] [Abstract][Full Text] [Related]
6. Effect of mTOR Inhibition with Sirolimus on Natural Killer Cell Reconstitution in Allogeneic Stem Cell Transplantation.
Haroun-Izquierdo A; Lanuza PM; Pfefferle A; Netskar H; Ask EH; Törlén J; Björklund A; Sohlberg E; Malmberg KJ
Transplant Cell Ther; 2023 Jun; 29(6):376.e1-376.e11. PubMed ID: 36966873
[TBL] [Abstract][Full Text] [Related]
7. Impact of Early Natural Killer Cell Reconstitution on the Outcomes of T Cell-Replete Allogeneic Hematopoietic Stem Cell Transplantation.
Zhou Z; Liu X; Zhang X; Wen S; Hua H; Wang Z; Xu Z; Lu Y; Wang F
J Inflamm Res; 2023; 16():2993-3008. PubMed ID: 37489148
[TBL] [Abstract][Full Text] [Related]
8. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
[TBL] [Abstract][Full Text] [Related]
9. Post-Transplantation Natural Killer Cell Count: A Predictor of Acute Graft-Versus-Host Disease and Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation.
Kim SY; Lee H; Han MS; Shim H; Eom HS; Park B; Kong SY
Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):527-535.e2. PubMed ID: 27375156
[TBL] [Abstract][Full Text] [Related]
10. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of mesenchymal stem cells co-infusion in allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis.
Li T; Luo C; Zhang J; Wei L; Sun W; Xie Q; Liu Y; Zhao Y; Xu S; Wang L
Stem Cell Res Ther; 2021 Apr; 12(1):246. PubMed ID: 33879242
[TBL] [Abstract][Full Text] [Related]
12. [Clinical Safety of NK Cell in the Prevention of Leukemia Relapse Post-transplantation and in Treatment of the Elderly Leukemia Patients].
Liu J; Zheng XL; Xue M; Zhu L; Ding L; Han DM; Yan HM; Li S; Ma JD; Tan XT; Zhou JX; Guo ZK; Wang HX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug; 30(4):1267-1271. PubMed ID: 35981396
[TBL] [Abstract][Full Text] [Related]
13. Quantity and Quality Reconstitution of NKG2A
Hu LJ; Zhao XY; Yu XX; Lv M; Han TT; Han W; Huang XJ
Biol Blood Marrow Transplant; 2019 Jan; 25(1):1-11. PubMed ID: 30142416
[TBL] [Abstract][Full Text] [Related]
14. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
Sahin U; Dalva K; Gungor F; Ustun C; Beksac M
Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic hematopoietic stem cell transplantation following donor CIK cell infusion: A phase I study in patients with relapsed/refractory hematologic malignancies.
Luo Y; Zeng HQ; Shen Y; Zhang P; Lou SF; Chen L; Deng JC
Leuk Res; 2016 Sep; 48():6-10. PubMed ID: 27416327
[TBL] [Abstract][Full Text] [Related]
16. Improved Relapse-Free Survival in Patients With High Natural Killer Cell Doses in Grafts and During Early Immune Reconstitution After Allogeneic Stem Cell Transplantation.
Minculescu L; Fischer-Nielsen A; Haastrup E; Ryder LP; Andersen NS; Schjoedt I; Friis LS; Kornblit BT; Petersen SL; Sengelov H; Marquart HV
Front Immunol; 2020; 11():1068. PubMed ID: 32547559
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxicity of Donor Natural Killer Cells to Allo-Reactive T Cells Are Related With Acute Graft-vs.-Host-Disease Following Allogeneic Stem Cell Transplantation.
Sheng L; Mu Q; Wu X; Yang S; Zhu H; Wang J; Lai Y; Wu H; Sun Y; Hu Y; Fu H; Wang Y; Xu K; Sun Y; Zhang Y; Zhang P; Zhou M; Lai B; Xu Z; Gao M; Zhang Y; Ouyang G
Front Immunol; 2020; 11():1534. PubMed ID: 32849519
[No Abstract] [Full Text] [Related]
18. The role of mesenchymal stem cells in hematopoietic stem cell transplantation: prevention and treatment of graft-versus-host disease.
Zhao L; Chen S; Yang P; Cao H; Li L
Stem Cell Res Ther; 2019 Jun; 10(1):182. PubMed ID: 31227011
[TBL] [Abstract][Full Text] [Related]
19. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Inducers of Natural Killer cell Killing (ThINKK): preclinical assessment of safety and efficacy in allogeneic hematopoietic stem cell transplant settings.
Poirier N; Paquin V; Leclerc S; Lisi V; Marmolejo C; Affia H; Cordeiro P; Théorêt Y; Haddad E; Andelfinger G; Lavallée VP; Duval M; Herblot S
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38754915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
